Abiopharma

RadNet Names Four Leaders to Expanded Executive Roles

EUDA Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement

Labeling changes approved for RISING. Active ingredient: MECLIZINE HYDROCHLORIDE. Decision date: 01/06/2026

Mersana Therapeutics (MRSN) was removed from the list of traded instruments on NASDAQ exchange

CureVac (CVAC) was removed from the list of traded instruments on NASDAQ exchange

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016

Interested Person Transaction: RENEWAL OF TENANCY AGREEMENT WITH CHEE AND HEAH SURGICAL ASSOCIATES PTE. LTD.

NASDAQ symbol attribute type Security_Name was changed. Previous value: Mersana Therapeutics, Inc. - Common Stock. New value: Mersana Therapeutics, Inc. - Common Stock.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: N. New value: Mersana Therapeutics, Inc. - Common Stock.

NASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: Mersana Therapeutics, Inc. - Common Stock.

NASDAQ symbol attribute type Test_mode was changed. Previous value: N. New value: CureVac N.V. - Ordinary Shares.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: N. New value: CureVac N.V. - Ordinary Shares.

NASDAQ symbol attribute type Security_Name was changed. Previous value: CureVac N.V. - Ordinary Shares. New value: CureVac N.V. - Ordinary Shares.

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B

Innate Pharma - Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025